Abstract

Urinary tract infections (UTIs) are infectious disorders that afflict both men and women. Drug-resistant bacteria are becoming more common in UTI patients. India has the world's highest rate of extended-spectrum -lactamase (ESBL)-producing microbes. Oral administration is required since it is the preferred dose form and route for patients released from the hospital. Clinicians in India frequently prescribe an alternate to intravenous carbapenems. Faropenem is an antibiotic that is taken orally and belongs to the "penems" class of - lactam antibiotics. Faropenem is increasingly popular among Indian urologists because to its broad range antibacterial action and lesser risk of resistance; nonetheless, real-world evidence is limited. Faropenem possesses wide antibacterial action against aerobic gram-positive, gram-negative, and anaerobic bacteria, as well as resistance to TEM, SHV, and CTX-M-type ESBLs. Faropenem is licenced in India for the treatment of infections of the respiratory tract, urinary tract, skin, soft tissue, and gynaecology. It is frequently used to treat invasive ESBL-producing Enterobacteriaceae infections, despite the fact that its effectiveness in these circumstances has not been shown clinically. Faropenem has little practical clinical experiences at the urologists level.

Description